Bioxytran (Bioxytran) Days Payable : 0.00 (As of Mar. 2024)

View and export this data going back to 2009. Start your Free Trial

What is Bioxytran Days Payable?

Bioxytran's average Accounts Payable for the three months ended in Mar. 2024 was $0.00 Mil. Bioxytran's Cost of Goods Sold for the three months ended in Mar. 2024 was $0.00 Mil.

The historical rank and industry rank for Bioxytran's Days Payable or its related term are showing as below:

During the past 13 years, Bioxytran's highest Days Payable was 393.18. The lowest was 129.86. And the median was 251.40.

BIXT's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 148.28
* Ranked among companies with meaningful Days Payable only.

Bioxytran's Days Payable stayed the same from Mar. 2023 (0.00) to Mar. 2024 (0.00). stayed the same

Bioxytran Days Payable Historical Data

The historical data trend for Bioxytran's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bioxytran Days Payable Chart

Bioxytran Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Payable

Get a 7-Day Free Trial

Bioxytran Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Days Payable	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Bioxytran's Days Payable

For the Biotechnology subindustry, Bioxytran's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bioxytran's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bioxytran's Days Payable distribution charts can be found below:

* The bar in red indicates where Bioxytran's Days Payable falls into.

Bioxytran Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Bioxytran's Days Payable for the fiscal year that ended in Dec. 2023 is calculated as

	Days Payable (A: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2022 )	+	Accounts Payable (A: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2023 )	*	Days in Period
=	( (0.001	+	0.002)	/	2 )	/	0	*	365
=	0.0015					/	0	*	365
=	N/A

Bioxytran's Days Payable for the quarter that ended in Mar. 2024 is calculated as:

	Days Payable (Q: Mar. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Dec. 2023 )	+	Accounts Payable (Q: Mar. 2024 ))	/	count )	/	Cost of Goods Sold (Q: Mar. 2024 )	*	Days in Period
=	( (0.002	+	0.001)	/	2 )	/	0	*	365 / 4
=	0.0015					/	0	*	365 / 4
=	N/A

Bioxytran Days Payable Related Terms

Thank you for viewing the detailed overview of Bioxytran's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Bioxytran (Bioxytran) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bioxytran Inc (OTCPK:BIXT) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

N/A

Address

75 2nd Avenue, Suite 605, Needham, MA, USA, 02494

Website

https://www.bioxytraninc.com

Bioxytran Inc is a biopharmaceutical company. The company is engaged in developing anti-necrosis drugs that treat a variety of medical conditions resulting from Ischemia. It is also focusing on the development and commercialization of treatments to prevent catastrophic brain damage resulting from hypoxic conditions following brain stroke. Its product candidate, BXT-25, is an anti-necrosis drug that carries oxygen to tissues when the flow of blood is blocked. Its other drug candidate BXT-252 is a resuscitative agent in a variety of wound healing applications.

Executives

Dale H Conaway	director	189 WELLS AVE, NEWTON MA 02459
Alan M Hoberman	director	6134 MECHANICSVILLE ROAD, PO BOX 56, MECHANICSVILLE PA 18934
Anders Utter	director	BIOXYTRAN, INC, 233 NEEDHAM ST., SUITE 300, NEWTON MA 02464
David Platt	director, 10 percent owner, officer: CEO	12 APPLETON CIRCLE, NEWTON MA 02459
Hana Chen-walden	director	7 RUE ARISTIDE MAILLOL, PARIS I0 75015
Michael Sheikh	officer: Chief Communication Officer	1905 S AUDUBON CT, SPOKANE WA 99224
Binder Offer	other: No longer 10% owner	PASQUALE VIA SETTEMBRIMI 14A, SAN MARIANO 06073, CORCIANO PG ITALY L6 00000
Ola Soderquist	10 percent owner, officer: CFO	47 HAMMOND STREET, UNIT 2, WALTHAM MA 02451
Lawrence W. Bonafide	director	78365 HWY 111, SUITE 287, LA QUINTA CA 92253
Nathan Marks	director	78365 HWY 111, SUITE 287, LA QUINTA CA 92253
Dave Quincy Farber	director, officer: President	78365 HWY 111, SUITE 287, LA QUINTA CA 92253
David Lee	director	78365 HWY 111, SUITE 287, LA QUINTA CA 92253
Donita R. Kendig	director, officer: Secretary/Treasurer	78365 HWY 11, SUITE 287, LA QUINTA CA 92253
Afcc, Llc	10 percent owner	1621 CENTRAL AVENUE, CHEYENNE WY 82001
Paul W Hai	10 percent owner	20443 TIMBERLINE, BEND OR 97701